Toxicity issues in cancer drug development

Current Opinion in Investigational Drugs

Volumn 11, Issue 6, 2010, Pages 612-614

  Gewirtz, David A ^a   Bristol, Molly L ^a   Yalowich, Jack C ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EXEMESTANE; IMATINIB; LETROZOLE; MONOCLONAL ANTIBODY; RALOXIFENE; RITUXIMAB; SUNITINIB; TAMOXIFEN;

BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME REARRANGEMENT; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; UTERUS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS;

EID: 77952943096     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)